자폐스펙트럼장애 임상시험 현황 : 동향과 분석(2026년판)

Autism Spectrum Disorder (ASD) is a complex neurodevelopmental condition characterized by persistent challenges in social communication, restricted interests, and repetitive behaviors. The disorder presents across a broad spectrum of severity and is frequently associated with comorbid conditions such as anxiety, attention-deficit/hyperactivity disorder (ADHD), epilepsy, sleep disorders, and gastrointestinal complications. Although behavioral interventions remain the standard of care, the growing need for therapies targeting the core symptoms of ASD has accelerated global clinical research. Pharmaceutical companies, biotechnology firms, academic institutions, and government organizations are increasingly investing in innovative therapeutic approaches, making clinical trial landscape analysis essential for understanding development trends, competitive dynamics, and future market opportunities.

Clinical trials landscape analysis provides comprehensive insights into ongoing and completed studies, investigational therapies, development phases, sponsor activities, regulatory progress, patient recruitment trends, and emerging treatment strategies. These analyses help stakeholders evaluate research priorities, pipeline maturity, commercialization potential, and investment opportunities within the evolving ASD therapeutic ecosystem.

Market Drivers

Growing Clinical Research Activity

One of the primary drivers of market growth is the substantial increase in clinical research focused on ASD therapeutics. Researchers are evaluating innovative pharmacological agents designed to address both the core symptoms of autism and associated behavioral and neurological complications.

Increasing collaboration between pharmaceutical companies, academic medical centers, and research organizations has accelerated the number of multinational clinical trials evaluating novel treatment approaches.

Rising Prevalence of Autism Spectrum Disorder

The growing global prevalence of ASD has increased demand for effective therapeutic interventions and strengthened investment in clinical development. Earlier diagnosis, expanded screening programs, and improved awareness are contributing to larger diagnosed patient populations that support clinical research initiatives.

Advances in Precision Medicine

Improved understanding of ASD genetics, neurobiology, biomarkers, and patient heterogeneity is supporting more personalized treatment strategies. Precision medicine approaches enable better patient stratification, improved trial design, and more targeted evaluation of investigational therapies.

Increasing Government and Regulatory Support

Governments and regulatory agencies continue to encourage research into neurodevelopmental disorders through research funding, orphan drug incentives where applicable, accelerated development pathways, and pediatric research initiatives. These measures are helping stimulate innovation across the ASD clinical pipeline.

Market Restraints

Clinical Heterogeneity

The highly heterogeneous nature of ASD creates challenges in patient selection, endpoint determination, and assessment of treatment efficacy, increasing the complexity of clinical trial design.

Limited Approved Pharmacological Options

While numerous investigational therapies are under development, few approved medications directly address the core symptoms of ASD, making clinical development scientifically challenging and commercially competitive.

Long Development Timelines

Clinical studies often require extended observation periods to evaluate behavioral improvements, developmental outcomes, long-term safety, and durability of treatment response, increasing both development costs and trial duration.

Clinical Trial and Technology Insights

The global ASD clinical trials landscape can be segmented by development phase, therapeutic modality, mechanism of action, sponsor type, patient population, and geography.

By development phase, the market includes preclinical research, Phase I, Phase II, Phase III, extension studies, and post-marketing investigations. The pipeline demonstrates active development across early- and mid-stage programs, while several late-stage studies continue to evaluate therapies targeting core ASD symptoms.

By therapeutic modality, the market includes small molecules, biologics, gene-based therapies, cell therapies, microbiome-based therapies, neuropeptides, and digital therapeutics. Behavioral intervention studies and combination treatment approaches also represent important areas of ongoing research.

By mechanism of action, investigational therapies target neurotransmitter modulation, synaptic function, neuroinflammation, oxytocin signaling, GABA and glutamate pathways, immune regulation, and gut-brain axis interactions.

By sponsor type, the market includes pharmaceutical companies, biotechnology firms, academic institutions, government research agencies, contract research organizations, and non-profit organizations.

Technological innovations such as artificial intelligence-assisted trial design, wearable digital biomarkers, remote patient monitoring, telemedicine, decentralized clinical trials, electronic outcome assessments, and real-world evidence integration are improving study efficiency, patient engagement, and data quality.

Clinical Development Trends

Clinical development within ASD has expanded considerably as researchers pursue therapies capable of addressing both core symptoms and associated behavioral challenges.

Current research priorities include:

• Developing therapies targeting core social communication deficits.
• Improving behavioral flexibility and adaptive functioning.
• Addressing associated conditions such as anxiety, sleep disorders, irritability, and ADHD.
• Identifying biomarker-guided patient subgroups for personalized therapies.
• Integrating digital technologies into behavioral assessment and long-term patient monitoring.

Increasing collaboration between academic researchers, biotechnology innovators, patient advocacy organizations, and healthcare providers is accelerating translational research and therapeutic innovation.

Regional Insights

North America remains the leading region for ASD clinical research due to strong pharmaceutical investment, extensive academic research infrastructure, favorable regulatory support, and high diagnosis rates. The United States accounts for a significant proportion of global ASD clinical trials.

Europe represents another major research hub supported by collaborative neuroscience initiatives, established pediatric research networks, and strong public healthcare systems.

Asia-Pacific is expected to witness rapid growth owing to expanding clinical research capabilities, increasing healthcare investment, rising autism awareness, and improving diagnostic infrastructure across countries such as Japan, China, South Korea, Australia, and India.

Latin America and the Middle East & Africa are gradually expanding participation in multinational ASD clinical trials through improving healthcare infrastructure and increased research collaboration.

Competitive Landscape

The ASD clinical trials landscape is characterized by participation from global pharmaceutical companies, biotechnology firms, academic medical centers, pediatric neuroscience institutes, and specialized neurodevelopmental research organizations.

Industry participants continue to invest in novel therapeutic targets, digital therapeutics, biomarker discovery, gene-based technologies, and precision medicine approaches. Strategic collaborations, licensing agreements, public-private partnerships, and research alliances are accelerating clinical development and strengthening competitive positioning.

Growing interest in therapies targeting the core symptoms of ASD, rather than only associated behavioral conditions, is reshaping the competitive landscape and expanding future commercial opportunities.

Future Outlook

The future of the ASD clinical trials landscape is expected to be driven by continued advances in neuroscience, genetics, biomarker research, artificial intelligence, and digital health technologies. Personalized medicine, genomics, microbiome research, and innovative neurodevelopmental therapies are expected to improve clinical trial success rates and expand treatment options.

The increasing use of decentralized clinical trials, wearable monitoring technologies, digital behavioral assessments, and real-world evidence platforms is expected to improve recruitment efficiency, enhance patient participation, and accelerate regulatory development.

As more investigational therapies progress through late-stage clinical development, the ASD therapeutic landscape is expected to become increasingly diversified, offering new opportunities to address both core symptoms and associated comorbidities.

Conclusion

The global Autism Spectrum Disorder clinical trials landscape, developments, and analysis market is poised for substantial growth through 2035, supported by expanding clinical research, increasing investment in neurodevelopmental disorders, advances in precision medicine, and continuous innovation in digital clinical trial technologies. While challenges related to disease heterogeneity, endpoint selection, and long development timelines remain, ongoing progress in neuroscience, genetics, biomarker discovery, and novel therapeutic platforms is expected to transform ASD treatment development. As more innovative therapies advance through the clinical pipeline, the market is likely to experience significant improvements in research productivity, therapeutic innovation, and long-term patient outcomes.

Key Benefits of this Report

• Insightful Analysis: Comprehensive evaluation of ASD clinical trials, pipeline activity, and emerging therapeutic trends.
• Competitive Landscape: Understand sponsor activities, clinical development strategies, and evolving competitive dynamics.
• Market Drivers and Future Trends: Assess innovation trends, regulatory developments, and future research opportunities.
• Actionable Recommendations: Support clinical development planning, licensing strategies, investment decisions, and partnership evaluations.
• Caters to a Wide Audience: Suitable for pharmaceutical companies, biotechnology firms, researchers, healthcare providers, investors, consultants, and policymakers.

What Businesses Use Our Reports For

Clinical trial monitoring, pipeline benchmarking, competitive intelligence, licensing assessments, partnership evaluations, investment planning, regulatory strategy development, portfolio management, and identification of emerging therapeutic opportunities.

Report Coverage

• Historical data from 2021 to 2025, Base year 2025, and Forecast years from 2026 to 2035
• Clinical trial analysis by development phase, therapeutic modality, mechanism of action, sponsor type, and geography
• Assessment of ongoing, completed, and emerging clinical development programs
• Competitive intelligence, regulatory developments, strategic collaborations, and research activity
• Future innovation trends, pipeline opportunities, commercialization outlook, and long-term market forecasts.

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Report Scope and Objectives
• 1.2 Clinical Trials Landscape Overview
• 1.3 Key Findings
• 1.4 Pipeline and Development Highlights
• 1.5 Clinical Research Trends
• 1.6 Key Sponsors and Developers
• 1.7 Unmet Medical Needs
• 1.8 Future Outlook

2. Autism Spectrum Disorder Overview

• 2.1 Introduction to Autism Spectrum Disorder (ASD)
• 2.2 Disease Classification
  • 2.2.1 Level 1 ASD
  • 2.2.2 Level 2 ASD
  • 2.2.3 Level 3 ASD
  • 2.2.4 Syndromic Autism
  • 2.2.5 Non-Syndromic Autism
• 2.3 Disease Pathophysiology
• 2.4 Genetic and Neurobiological Mechanisms
• 2.5 Clinical Manifestations
• 2.6 Current Treatment Landscape
• 2.7 Limitations of Available Therapies
• 2.8 Unmet Clinical Needs

3. Clinical Development Landscape

• 3.1 Evolution of ASD Drug Development
• 3.2 Historical Clinical Development Trends
• 3.3 Current Research Priorities
• 3.4 Clinical Development Challenges
• 3.5 Innovation Trends in ASD Research
• 3.6 Future Clinical Development Directions

4. Clinical Trial Landscape Analysis

• 4.1 Global Clinical Trial Overview
• 4.2 Clinical Trials by Development Phase
  • 4.2.1 Early Phase I
  • 4.2.2 Phase I
  • 4.2.3 Phase II
  • 4.2.4 Phase III
  • 4.2.5 Phase IV
• 4.3 Clinical Trials by Study Status
  • 4.3.1 Recruiting
  • 4.3.2 Active, Not Recruiting
  • 4.3.3 Completed
  • 4.3.4 Enrolling by Invitation
  • 4.3.5 Withdrawn
  • 4.3.6 Terminated
• 4.4 Clinical Trials by Sponsor Type
  • 4.4.1 Industry Sponsored
  • 4.4.2 Academic Sponsored
  • 4.4.3 Government Sponsored
  • 4.4.4 Non-Profit Organizations
• 4.5 Clinical Trials by Intervention Type
  • 4.5.1 Drug Studies
  • 4.5.2 Biologic Studies
  • 4.5.3 Behavioral Intervention Studies
  • 4.5.4 Device-Based Studies
  • 4.5.5 Combination Therapy Studies

5. Clinical Trials Segmentation

• 5.1 By Therapeutic Target
  • 5.1.1 Core Social Communication Deficits
  • 5.1.2 Repetitive Behaviors
  • 5.1.3 Irritability and Aggression
  • 5.1.4 Anxiety and Mood Symptoms
  • 5.1.5 Sleep Disorders
  • 5.1.6 Cognitive and Executive Function Deficits
• 5.2 By Molecule Type
  • 5.2.1 Small Molecules
  • 5.2.2 Biologics
  • 5.2.3 Gene Therapies
  • 5.2.4 RNA-Based Therapies
  • 5.2.5 Microbiome-Based Therapies
• 5.3 By Route of Administration
  • 5.3.1 Oral
  • 5.3.2 Injectable
  • 5.3.3 Intranasal
  • 5.3.4 Intravenous
• 5.4 By Patient Population
  • 5.4.1 Pediatric Population
  • 5.4.2 Adolescent Population
  • 5.4.3 Adult Population
• 5.5 By Disease Type
  • 5.5.1 Syndromic Autism
  • 5.5.2 Non-Syndromic Autism
  • 5.5.3 Fragile X Syndrome with ASD
  • 5.5.4 Rett Syndrome with ASD Features

6. Mechanism of Action Analysis

• 6.1 Vasopressin Receptor Modulators
• 6.2 Oxytocin Pathway Modulators
• 6.3 Glutamatergic Modulators
• 6.4 GABAergic Modulators
• 6.5 Serotonergic Modulators
• 6.6 Dopaminergic Modulators
• 6.7 Microbiome-Based Therapeutics
• 6.8 Neuroinflammation Targets
• 6.9 Synaptic Function Modulators
• 6.10 Novel Mechanisms Under Investigation

7. Active Clinical Trial Assessment

• 7.1 Phase I Clinical Trials Analysis
• 7.2 Phase II Clinical Trials Analysis
• 7.3 Phase III Clinical Trials Analysis
• 7.4 Ongoing Recruitment Trends
• 7.5 Patient Enrollment Analysis
• 7.6 Primary and Secondary Endpoints Assessment
• 7.7 Expected Trial Readouts and Milestones

8. Completed Clinical Trial Assessment

• 8.1 Completed Trial Overview
• 8.2 Trial Outcome Analysis
• 8.3 Efficacy Assessment Trends
• 8.4 Safety and Tolerability Trends
• 8.5 Lessons from Failed Trials
• 8.6 Clinical Development Success Factors

9. Clinical Trial Benchmarking and Competitive Analysis

• 9.1 Clinical Development Benchmarking
• 9.2 Sponsor Competitiveness Analysis
• 9.3 Pipeline Strength Assessment
• 9.4 Innovation Benchmarking
• 9.5 Strategic Collaborations and Partnerships
• 9.6 Licensing and Co-Development Agreements
• 9.7 Mergers and Acquisitions
• 9.8 Competitive Positioning Matrix

10. Geographical Analysis

• 10.1 North America
  • 10.1.1 Clinical Trial Volume
  • 10.1.2 Research Infrastructure
  • 10.1.3 Regulatory Environment
  • 10.1.4 Funding Trends
  • 10.1.5 Growth Opportunities
• 10.2 Europe
  • 10.2.1 Clinical Trial Volume
  • 10.2.2 Research Infrastructure
  • 10.2.3 Regulatory Environment
  • 10.2.4 Funding Trends
  • 10.2.5 Growth Opportunities
• 10.3 Asia-Pacific
  • 10.3.1 Clinical Trial Volume
  • 10.3.2 Research Infrastructure
  • 10.3.3 Regulatory Environment
  • 10.3.4 Funding Trends
  • 10.3.5 Growth Opportunities
• 10.4 Latin America
  • 10.4.1 Clinical Trial Volume
  • 10.4.2 Research Infrastructure
  • 10.4.3 Regulatory Environment
  • 10.4.4 Funding Trends
  • 10.4.5 Growth Opportunities
• 10.5 Middle East & Africa
  • 10.5.1 Clinical Trial Volume
  • 10.5.2 Research Infrastructure
  • 10.5.3 Regulatory Environment
  • 10.5.4 Funding Trends
  • 10.5.5 Growth Opportunities

11. Key Countries Analysis

• 11.1 United States
  • 11.1.1 Clinical Trial Volume
  • 11.1.2 Research Infrastructure
  • 11.1.3 Regulatory Environment
  • 11.1.4 Funding Trends
  • 11.1.5 Growth Opportunities
• 11.2 Canada
  • 11.2.1 Clinical Trial Volume
  • 11.2.2 Research Infrastructure
  • 11.2.3 Regulatory Environment
  • 11.2.4 Funding Trends
  • 11.2.5 Growth Opportunities
• 11.3 Germany
  • 11.3.1 Clinical Trial Volume
  • 11.3.2 Research Infrastructure
  • 11.3.3 Regulatory Environment
  • 11.3.4 Funding Trends
  • 11.3.5 Growth Opportunities
• 11.4 United Kingdom
  • 11.4.1 Clinical Trial Volume
  • 11.4.2 Research Infrastructure
  • 11.4.3 Regulatory Environment
  • 11.4.4 Funding Trends
  • 11.4.5 Growth Opportunities
• 11.5 France
  • 11.5.1 Clinical Trial Volume
  • 11.5.2 Research Infrastructure
  • 11.5.3 Regulatory Environment
  • 11.5.4 Funding Trends
  • 11.5.5 Growth Opportunities
• 11.6 Italy
  • 11.6.1 Clinical Trial Volume
  • 11.6.2 Research Infrastructure
  • 11.6.3 Regulatory Environment
  • 11.6.4 Funding Trends
  • 11.6.5 Growth Opportunities
• 11.7 Spain
  • 11.7.1 Clinical Trial Volume
  • 11.7.2 Research Infrastructure
  • 11.7.3 Regulatory Environment
  • 11.7.4 Funding Trends
  • 11.7.5 Growth Opportunities
• 11.8 China
  • 11.8.1 Clinical Trial Volume
  • 11.8.2 Research Infrastructure
  • 11.8.3 Regulatory Environment
  • 11.8.4 Funding Trends
  • 11.8.5 Growth Opportunities
• 11.9 Japan
  • 11.9.1 Clinical Trial Volume
  • 11.9.2 Research Infrastructure
  • 11.9.3 Regulatory Environment
  • 11.9.4 Funding Trends
  • 11.9.5 Growth Opportunities
• 11.10 India
  • 11.10.1 Clinical Trial Volume
  • 11.10.2 Research Infrastructure
  • 11.10.3 Regulatory Environment
  • 11.10.4 Funding Trends
  • 11.10.5 Growth Opportunities
• 11.11 South Korea
  • 11.11.1 Clinical Trial Volume
  • 11.11.2 Research Infrastructure
  • 11.11.3 Regulatory Environment
  • 11.11.4 Funding Trends
  • 11.11.5 Growth Opportunities
• 11.12 Australia
  • 11.12.1 Clinical Trial Volume
  • 11.12.2 Research Infrastructure
  • 11.12.3 Regulatory Environment
  • 11.12.4 Funding Trends
  • 11.12.5 Growth Opportunities

12. Company Profiles

• 12.1 Roche
  • 12.1.1 Overview
  • 12.1.2 Financials
  • 12.1.3 Autism Spectrum Disorder Clinical Pipeline
  • 12.1.4 Clinical Development Strategy
  • 12.1.5 Key Drug Candidates
  • 12.1.6 Clinical Trial Programs
  • 12.1.7 Strategic Collaborations
  • 12.1.8 Recent Developments
• 12.2 Yamo Pharmaceuticals
  • 12.2.1 Overview
  • 12.2.2 Financials
  • 12.2.3 Autism Spectrum Disorder Clinical Pipeline
  • 12.2.4 Clinical Development Strategy
  • 12.2.5 Key Drug Candidates
  • 12.2.6 Clinical Trial Programs
  • 12.2.7 Strategic Collaborations
  • 12.2.8 Recent Developments
• 12.3 Stalicla SA
  • 12.3.1 Overview
  • 12.3.2 Financials
  • 12.3.3 Autism Spectrum Disorder Clinical Pipeline
  • 12.3.4 Clinical Development Strategy
  • 12.3.5 Key Drug Candidates
  • 12.3.6 Clinical Trial Programs
  • 12.3.7 Strategic Collaborations
  • 12.3.8 Recent Developments
• 12.4 Axial Therapeutics
  • 12.4.1 Overview
  • 12.4.2 Financials
  • 12.4.3 Autism Spectrum Disorder Clinical Pipeline
  • 12.4.4 Clinical Development Strategy
  • 12.4.5 Key Drug Candidates
  • 12.4.6 Clinical Trial Programs
  • 12.4.7 Strategic Collaborations
  • 12.4.8 Recent Developments
• 12.5 SciSparc Ltd.
  • 12.5.1 Overview
  • 12.5.2 Financials
  • 12.5.3 Autism Spectrum Disorder Clinical Pipeline
  • 12.5.4 Clinical Development Strategy
  • 12.5.5 Key Drug Candidates
  • 12.5.6 Clinical Trial Programs
  • 12.5.7 Strategic Collaborations
  • 12.5.8 Recent Developments
• 12.6 Oryzon Genomics S.A.
  • 12.6.1 Overview
  • 12.6.2 Financials
  • 12.6.3 Autism Spectrum Disorder Clinical Pipeline
  • 12.6.4 Clinical Development Strategy
  • 12.6.5 Key Drug Candidates
  • 12.6.6 Clinical Trial Programs
  • 12.6.7 Strategic Collaborations
  • 12.6.8 Recent Developments
• 12.7 Curemark, LLC
  • 12.7.1 Overview
  • 12.7.2 Financials
  • 12.7.3 Autism Spectrum Disorder Clinical Pipeline
  • 12.7.4 Clinical Development Strategy
  • 12.7.5 Key Drug Candidates
  • 12.7.6 Clinical Trial Programs
  • 12.7.7 Strategic Collaborations
  • 12.7.8 Recent Developments
• 12.8 Neurochlore SAS
  • 12.8.1 Overview
  • 12.8.2 Financials
  • 12.8.3 Autism Spectrum Disorder Clinical Pipeline
  • 12.8.4 Clinical Development Strategy
  • 12.8.5 Key Drug Candidates
  • 12.8.6 Clinical Trial Programs
  • 12.8.7 Strategic Collaborations
  • 12.8.8 Recent Developments
• 12.9 Jazz Pharmaceuticals plc
  • 12.9.1 Overview
  • 12.9.2 Financials
  • 12.9.3 Autism Spectrum Disorder Clinical Pipeline
  • 12.9.4 Clinical Development Strategy
  • 12.9.5 Key Drug Candidates
  • 12.9.6 Clinical Trial Programs
  • 12.9.7 Strategic Collaborations
  • 12.9.8 Recent Developments
• 12.10 Servier
  • 12.10.1 Overview
  • 12.10.2 Financials
  • 12.10.3 Autism Spectrum Disorder Clinical Pipeline
  • 12.10.4 Clinical Development Strategy
  • 12.10.5 Key Drug Candidates
  • 12.10.6 Clinical Trial Programs
  • 12.10.7 Strategic Collaborations
  • 12.10.8 Recent Developments

13. Trial Site and Investigator Landscape

• 13.1 Leading Trial Centers
• 13.2 Academic Research Networks
• 13.3 Principal Investigator Analysis
• 13.4 Site Performance Benchmarking
• 13.5 Patient Recruitment Networks
• 13.6 Future Research Infrastructure Development

14. Future Outlook and Strategic Recommendations

• 14.1 Future Clinical Development Trends
• 14.2 Emerging Therapeutic Modalities
• 14.3 Regulatory Outlook
• 14.4 Partnership and Licensing Opportunities
• 14.5 Investment Trends
• 14.6 Commercialization Challenges
• 14.7 Long-Term Clinical Development Outlook (2025-2045)

15. Research Methodology

• 15.1 Primary Research
• 15.2 Secondary Research
• 15.3 Clinical Trial Intelligence Methodology
• 15.4 Pipeline Assessment Framework
• 15.5 Data Validation and Triangulation
• 15.6 Forecasting Methodology

16. Appendix

• 16.1 Abbreviations
• 16.2 Glossary of Terms
• 16.3 References
• 16.4 List of Tables
• 16.5 List of Figures
• 16.6 ClinicalTrials.gov Sources
• 16.7 Regulatory Sources
• 16.8 Company Sources
• 16.9 Scientific Literature Sources